Objective: To compare the effect of Endostar in combination with chemotherapy for colorectal cancer with effect of chemotherapy alone.
Methodology: Take excluded criteria to select previous researches, evaluate the risk of bias and then propose the meta-analysis. The combined effect size is Odd Ratio (OR). If there is a negative result in the heterogeneity test, subjects can be combined by the fixed effects model, otherwise a sensitive test is proposed, negative sensitive researches cannot pass through into fixed effects model.
Results: Totally, there are 16 prospective cohort studies having a low risk of bias included in the metaanalysis. Compared with accepting chemotherapy alone, patients with Endostar therapy in combination with chemotherapy have significant improved outcomes, the probability of outcomes improvement increased 59 times(RR=1.59, 95% CI: 1.34,1.89). I2 value is 0%, indicating a low heterogeneity.
Conclusion: In conclusion, compared with chemotherapy alone, Endostar treatment of colorectal cancer in combination with chemotherapy has a better effect rather than chemotherapy alone based on RR +CR.